miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma

A multiple receptor tyrosine kinase inhibitor, sunitinib, is a first-line therapy for clear cell renal cell carcinoma (CCRCC). Unfortunately, it has the major challenges of low initial response rate and resistance after about one year of treatment. Here we evaluated a microRNA (miRNA) and its target...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sang Eun, Kim, Wonju, Hong, Ji-Ye, Kang, Dayeon, Park, Seulki, Suh, Jungyo, You, Dalsan, Park, Yun-Yong, Suh, Nayoung, Hwang, Jung Jin, Kim, Choung-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894382/
https://www.ncbi.nlm.nih.gov/pubmed/35241735
http://dx.doi.org/10.1038/s41598-022-07468-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894382/
https://www.ncbi.nlm.nih.gov/pubmed/35241735
http://dx.doi.org/10.1038/s41598-022-07468-x

Ejemplares similares